According to a report released by Pudong on December 28, Shanghai Minimally Invasive Medical Robot (Group) Co., Ltd. (hereinafter referred to as "Minimally Invasive Robot"), a subsidiary of MicroPort Medical Science Co., Ltd. (hereinafter referred to as "MicroPort Group"), recently announced that its self-developed Marie Curie unmanned automatic surgical platform (hereinafter referred to as "Marie Curie") has tried animal experiments on prostatic hyperplasia interventional cryoablation surgery for the first time and succeeded, which marks that Marie Curie has initially possessed the fully automatic surgical capability of percutaneous puncture. It is also an important milestone in the research of minimally invasive robot fully automated surgery.
According to the latest data of Wisdom Bud, Shanghai Microport Medical Robot (Group) Co., Ltd. has published 297 patent applications since 2015, including 253 non-appearance patents, accounting for 85.19%, of which 244 invention patents, 9 utility models, and 128 core patents have been cited.
In addition, it is worth noting that there are 123 patents in the trial of minimally invasive robots, accounting for more than 40%, indicating that the company's recent innovation vitality is very high.
![A surgery of 30,000 pieces, the world every 26 seconds of 1 person has done, the United States robot monopoly market for 22 years[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)